Article Text

Download PDFPDF
Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone
  1. Elizabeth F Shead1,
  2. Charles S Haworth2,
  3. Alison M Condliffe3,
  4. Damian J McKeon4,
  5. Mike A Scott5,
  6. Juliet E Compston6
  1. 1Haematology Department, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  2. 2Adult Cystic Fibrosis Centre, Papworth Hospital NHS Foundation Trust, Cambridge, UK
  3. 3Department of Medicine, University of Cambridge, Cambridge, UK
  4. 4Adult Cystic Fibrosis Centre, Papworth Hospital NHS Foundation Trust, Cambridge and Department of Medicine, University of Cambridge, Cambridge, UK
  5. 5Haematology Department, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  6. 6Department of Medicine, University of Cambridge, Cambridge, UK
  1. Correspondence to:
    Dr Elizabeth Shead
    Haematology Department, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK; lizz.shead{at}addenbrookes.nhs.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Mutations within the CFTR gene are central to the pathophysiology of cystic fibrosis. CFTR encodes a chloride channel that is located primarily on epithelial cell membranes and is responsible for the regulation of transmembrane chloride and other ion transport. Recent studies indicate a potential association between mutation of the CFTR gene and osteoporosis in patients with CF. Dif et al1 reported an abnormal skeletal phenotype in CFTR-null mice with striking osteopenia, reduced cortical width and thinning of the trabeculae, while in a study of adults with CF, the ΔF508 mutation was shown to be an independent risk factor for low bone mineral density.2 An association between CFTR mutations and bone disease might be mediated either indirectly by effects of the mutations on other systems (for example, the endocrine system), or it could be due to abnormally …

View Full Text

Footnotes

  • Dr Elizabeth Shead was funded though a clinical scientist training programme supported by the Workforce Development Confederation.

  • Competing interests: None declared.